Trial Profile
A Randomized Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Bicalutamide; Goserelin; Leuprorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- 16 Mar 2021 Primary endpoint (Number of Patients Who Achieve a PSA 4ng/mL After Seven Months of Protocol Treatment in Each Arm description:) has been met as per results published in the Clinical Cancer Research.
- 16 Mar 2021 Results published in the Clinical Cancer Research
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology